Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL versus MECLIZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL versus MECLIZINE HYDROCHLORIDE.
BENADRYL vs MECLIZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; inverse agonist at histamine H1 receptors, blocking histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction; also anticholinergic and sedative.
Meclizine is a histamine H1 receptor antagonist that acts centrally in the vestibular system to suppress nausea and vomiting. It also has anticholinergic and sedative effects.
25-50 mg orally every 4-6 hours as needed; maximum 300 mg per day. Alternatively, 10-50 mg intramuscularly or intravenously once, maximum 100 mg per dose (IV route preferred).
25-50 mg orally, 3 to 4 times daily for vertigo; 25-50 mg orally 1 hour before travel, may repeat every 24 hours as needed for motion sickness.
None Documented
None Documented
Terminal elimination half-life 4-8 hours; prolonged in hepatic impairment (up to 20 hours).
Terminal elimination half-life: 6 hours (range 5-10 hours). Clinical context: Supports twice-daily dosing; steady-state achieved in approximately 24 hours.
Renal (90% as metabolites, <5% unchanged); minimal biliary/fecal.
Renal (unchanged and metabolites): 50%; fecal: 40%; biliary: 10%
Category C
Category A/B
Antihistamine
Antihistamine